On September 20, 2023, Heart Test Laboratories, Inc. entered into multiple definitive license agreements (collectively, the ?License Agreements?) with Icahn School of Medicine at Mount Sinai (?Mount Sinai?) to commercialize a range of AI-based cardiovascular algorithms developed by Mount Sinai, as well as a memorandum of understanding for ongoing cooperation. On December 1, 2023, the Company satisfied the Additional Financing requirement and, accordingly, the License Agreements are no longer subject to termination as a result of the Additional Financing condition. On December 1, 2023, the Company satisfied the Additional Financing requirement and, accordingly, the License Agreements are no longer subject to termination as a result of the Additional Financing condition, and the MTS Warrants are fully exercisable, by Mount Sinai.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.21 USD | -1.70% |
|
-0.76% | -69.53% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-69.53% | 3.47M | |
+0.56% | 3.25B | |
-9.32% | 160M | |
-16.67% | 78.05M |
- Stock Market
- Equities
- HSCS Stock
- News Heart Test Laboratories, Inc.
- Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai